Protara Therapeutics To Host Investor Webinar On TARA-002 Program And Treatment Landscape For Lymphatic Malformations On May 19, 2026

Protara Therapeutics, Inc.

Protara Therapeutics, Inc.

TARA

0.00

Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program

NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and regulatory path for TARA-002 and a review of clinical data supporting the use of TARA-002 in LMs.

The live event and accompanying slides can be accessed visiting the Events and Presentations section of the Company's website https://ir.protaratx.com. A replay of the webcast will be archived for a limited time following the event.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.